Stimulants and Cognitive Enhancers Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Stimulants and Cognitive Enhancers. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Stimulants and Cognitive Enhancers Indian Medical PG Question 1: Which of the following drugs are used in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD)?
- A. Atomoxetine
- B. Dexmethylphenidate
- C. Methylphenidate
- D. All of the options (Correct Answer)
Stimulants and Cognitive Enhancers Explanation: ***All of the options***
- **Atomoxetine**, **dexmethylphenidate**, and **methylphenidate** are all approved and commonly used medications for managing Attention-Deficit Hyperactivity Disorder (ADHD) [1].
- They represent different classes or formulations of drugs targeting neurotransmitter systems involved in ADHD.
*Atomoxetine*
- This is a **selective norepinephrine reuptake inhibitor** used for ADHD.
- It is a **non-stimulant** option, often preferred for patients who do not tolerate stimulants or have co-existing anxiety disorders.
*Dexmethylphenidate*
- This is the **dextro-isomer** of methylphenidate, and it is a **central nervous system (CNS) stimulant** [1].
- It is known for its **potency** and faster onset of action due to only containing the active isomer.
*Methylphenidate*
- This is a **CNS stimulant** medication that works by blocking the reuptake of norepinephrine and dopamine [1].
- It is available in various formulations (short-acting, intermediate-acting, long-acting) to suit individual patient needs [1].
Stimulants and Cognitive Enhancers Indian Medical PG Question 2: An SSRI antidepressant, such as fluoxetine, will be prescribed for an adult patient. You should advise him or her that two of the most likely side effects or adverse responses that may eventually occur at therapeutic blood levels are which of the following?
- A. Sexual dysfunction and sleep disturbances (Correct Answer)
- B. Sexual dysfunction and nausea
- C. Headache and diarrhea
- D. Tremor and weight gain
Stimulants and Cognitive Enhancers Explanation: ***Sexual dysfunction and sleep disturbances***
- **Sexual dysfunction** is one of the most common and persistent adverse effects of SSRIs, affecting 40-65% of patients and continuing throughout treatment at therapeutic levels [2], [3].
- **Sleep disturbances** (insomnia or altered sleep architecture) can persist during long-term SSRI therapy and are among the eventual side effects patients experience [1], [2], [3].
- Both effects are characteristic of chronic SSRI use and significantly impact patient compliance and quality of life.
*Sexual dysfunction and nausea*
- While **sexual dysfunction** is indeed very common and persistent, **nausea** is typically a transient side effect that occurs during the first 1-2 weeks of treatment and usually resolves with continued use [2].
- The question specifically asks about *eventual* occurrence at therapeutic levels over time, making nausea less appropriate as it is not a chronic issue.
*Tremor and weight gain*
- **Tremor** is not among the most common side effects of SSRIs and occurs less frequently than sexual dysfunction or sleep disturbances.
- **Weight gain** can occur with some SSRIs (particularly paroxetine), but fluoxetine is actually considered weight-neutral or may even cause weight loss in some patients, making this combination less likely for fluoxetine specifically [1].
*Headache and diarrhea*
- Both **headache** and **diarrhea** are common initial side effects when starting SSRIs but typically improve or resolve within the first few weeks of treatment [1].
- These are transient effects rather than eventual persistent side effects that characterize long-term therapeutic use.
Stimulants and Cognitive Enhancers Indian Medical PG Question 3: A 32-year-old man comes to the physician complaining of excessive sleepiness for the past several months. He reports falling asleep while dealing with customers and had a near accident when he fell asleep while driving. The patient reports that he occasionally hears voices while falling asleep and finds himself "temporarily frozen" and unable to move upon awakening. Which of the following is the most appropriate treatment for this patient?
- A. Melatonin
- B. Modafinil (Correct Answer)
- C. Clonazepam
- D. Continuous positive airway pressure
Stimulants and Cognitive Enhancers Explanation: ***Modafinil***
- The patient's symptoms of **excessive daytime sleepiness** (EDS), **hypnagogic hallucinations** (hearing voices while falling asleep), and **sleep paralysis** are classic signs of **narcolepsy**.
- **Modafinil** is a **non-amphetamine stimulant** that promotes wakefulness and is a first-line treatment for narcolepsy, improving alertness and reducing EDS.
*Melatonin*
- **Melatonin** is a hormone involved in regulating the **sleep-wake cycle** and is primarily used for **insomnia**, **jet lag**, or **circadian rhythm disorders**.
- It is not effective for treating the hallmark symptoms of narcolepsy, such as cataplexy or excessive daytime sleepiness.
*Clonazepam*
- **Clonazepam** is a **benzodiazepine** that acts as a central nervous system depressant, primarily used for **anxiety disorders**, seizures, and some sleep disorders like **REM sleep behavior disorder**.
- While it can help with some parasomnias, it would worsen daytime sleepiness in a patient with narcolepsy and is not a primary treatment for its core symptoms.
*Continuous positive airway pressure*
- **Continuous positive airway pressure (CPAP)** is the standard treatment for **obstructive sleep apnea (OSA)**, a condition characterized by recurrent upper airway collapse during sleep.
- Although OSA can cause excessive daytime sleepiness, the patient's additional symptoms of hypnagogic hallucinations and sleep paralysis are not typical of OSA, making narcolepsy and its specific treatments more appropriate.
Stimulants and Cognitive Enhancers Indian Medical PG Question 4: Which of the following is the most appropriate treatment for an overactive bladder in a patient with dementia?
- A. Tolterodine (Correct Answer)
- B. Mirabegron
- C. Behavioral therapy/bladder training
- D. Oxybutynin
- E. Trospium
Stimulants and Cognitive Enhancers Explanation: ***Tolterodine***
- **Tolterodine** is a **muscarinic antagonist** that blocks acetylcholine receptors in the bladder, reducing detrusor muscle contractions and overactive bladder symptoms.
- Unlike some other anticholinergics like oxybutynin, it has a **lower propensity to cross the blood-brain barrier** and thus a reduced risk of exacerbating cognitive impairment in patients with dementia.
*Mirabegron*
- **Mirabegron** is a **beta-3 adrenergic agonist** that relaxes the detrusor muscle, increasing bladder capacity.
- While it has a different mechanism of action and is less likely to cause anticholinergic cognitive side effects than older anticholinergics, it can still cause **hypertension** and **tachycardia**, which may be problematic in elderly patients with comorbidities.
*Behavioral therapy/bladder training*
- **Behavioral therapy** and **bladder training** are important first-line treatments for overactive bladder.
- However, for patients with **dementia**, cognitive impairment often makes adherence to and understanding of these complex therapies challenging or impossible without significant caregiver support.
*Oxybutynin*
- **Oxybutynin** is an **anticholinergic drug** that is effective for overactive bladder.
- However, it has a **high affinity for muscarinic receptors** in the brain and readily crosses the blood-brain barrier, significantly increasing the risk of **cognitive impairment, confusion, and delirium** in elderly patients, especially those with pre-existing dementia.
*Trospium*
- **Trospium** is a **quaternary amine anticholinergic** that is hydrophilic and has minimal blood-brain barrier penetration.
- While theoretically safer than oxybutynin in terms of CNS effects, it has **lower bladder selectivity** compared to tolterodine and may cause more peripheral anticholinergic side effects (dry mouth, constipation).
Stimulants and Cognitive Enhancers Indian Medical PG Question 5: Which of the following actions is NOT associated with tricyclic antidepressants?
- A. Block 5-HT or NE reuptake
- B. Anticholinergic action
- C. MAO inhibition (Correct Answer)
- D. Causes sedation
Stimulants and Cognitive Enhancers Explanation: ***MAO inhibition***
- Tricyclic antidepressants (TCAs) primarily exert their effects by inhibiting the reuptake of **norepinephrine** and **serotonin**, not by inhibiting monoamine oxidase (MAO).
- **MAO inhibitors** are a distinct class of antidepressants with a different mechanism of action and side effect profile.
*Anticholinergic action*
- Many TCAs have significant **anticholinergic effects**, blocking muscarinic receptors and leading to side effects like dry mouth, constipation, and blurred vision.
- These effects contribute to the **adverse event profile** of TCAs, especially in elderly patients.
*Block 5-HT or NE reuptake*
- The primary mechanism of action of TCAs involves the **inhibition of serotonin (5-HT)** and **norepinephrine (NE) reuptake** into presynaptic neurons.
- This action increases the concentration of these neurotransmitters in the **synaptic cleft**, thereby potentiating their effects.
*Causes sedation*
- TCAs frequently cause **sedation**, particularly the more histaminergic ones (e.g., amitriptyline, doxepin), due to their **histamine H1 receptor antagonism**.
- This side effect can be beneficial for patients with insomnia but can be problematic for daytime functioning.
Stimulants and Cognitive Enhancers Indian Medical PG Question 6: Atomoxetine is used in the management of which of the following conditions?
- A. Bipolar disorder
- B. Schizophrenia
- C. Depression
- D. ADHD (Correct Answer)
Stimulants and Cognitive Enhancers Explanation: ***Correct: ADHD***
* **Atomoxetine** is a **selective norepinephrine reuptake inhibitor (SNRI)** primarily used in the management of **Attention-Deficit/Hyperactivity Disorder (ADHD)**.
* It is a **non-stimulant** medication, making it a suitable alternative for patients who do not respond to or cannot tolerate traditional stimulant medications for ADHD.
* FDA-approved in 2002, atomoxetine remains an important treatment option, particularly for patients with concerns about stimulant abuse potential or those with comorbid anxiety disorders.
*Incorrect: Bipolar disorder*
* **Bipolar disorder** is typically treated with mood stabilizers (e.g., lithium, valproate), antipsychotics, and sometimes antidepressants, but atomoxetine is not a first-line or common treatment option.
* While some ADHD symptoms can overlap with bipolar disorder, atomoxetine is specifically designed for ADHD and lacks the broad mood-stabilizing effects needed for bipolar disorder.
*Incorrect: Schizophrenia*
* **Schizophrenia** is a severe mental disorder treated primarily with **antipsychotic medications** that target dopamine and serotonin systems.
* Atomoxetine does not have efficacy in treating the positive or negative symptoms of schizophrenia and is not indicated for this condition.
*Incorrect: Depression*
* While atomoxetine affects **norepinephrine**, some SNRIs (e.g., venlafaxine, duloxetine) are used for depression. However, atomoxetine's primary indication and efficacy profile are not for treating **major depressive disorder**.
* Its mechanism of action is more specifically tailored to the neurochemical imbalances seen in ADHD rather than the broader neurotransmitter dysregulation in depression.
Stimulants and Cognitive Enhancers Indian Medical PG Question 7: What is the treatment for extrapyramidal side effects induced by Haloperidol?
- A. Barbiturates
- B. SSRIs
- C. Benzodiazepines
- D. Anticholinergic drugs (Correct Answer)
Stimulants and Cognitive Enhancers Explanation: ***Anticholinergic drugs (effective treatment)***
- **Anticholinergic medications**, such as **benztropine** or **diphenhydramine**, are the primary treatment for **acute extrapyramidal symptoms (EPS)** like dystonia and parkinsonism induced by antipsychotics like haloperidol.
- They work by **blocking muscarinic acetylcholine receptors**, helping to restore the balance between dopamine and acetylcholine in the basal ganglia.
*Benzodiazepines (used for anxiety and muscle relaxation)*
- While benzodiazepines can offer some relief for **akathisia** (a form of EPS characterized by restlessness) due to their sedative and muscle relaxant properties, they are **not the first-line treatment for other acute EPS** such as dystonia or parkinsonism.
- They primarily enhance **GABAergic transmission** and are effective for anxiety and seizure control rather than direct antagonism of EPS mechanisms.
*Barbiturates (used as sedative-hypnotic drugs)*
- **Barbiturates** are strong central nervous system depressants used for sedation, anesthesia, and seizure control, but are **not indicated for the treatment of EPS**.
- Their significant **sedative and addictive potential**, along with a narrow therapeutic index, makes them unsuitable for this purpose.
*SSRIs (used for depression and anxiety)*
- **SSRIs (Selective Serotonin Reuptake Inhibitors)** are antidepressants that work by increasing serotonin levels in the brain and are used to treat depression, anxiety, and obsessive-compulsive disorder.
- They **do not have a direct role** in ameliorating dopamine-acetylcholine imbalance responsible for haloperidol-induced EPS.
Stimulants and Cognitive Enhancers Indian Medical PG Question 8: Drugs used in Alzheimer's disease are all EXCEPT:
- A. Biperidin (Correct Answer)
- B. Memantine
- C. Rivastigmine
- D. Donepezil
Stimulants and Cognitive Enhancers Explanation: ***Biperidin***
- **Biperidin** is an **anticholinergic drug** primarily used to treat **Parkinson's disease** and **drug-induced extrapyramidal symptoms**.
- Its **anticholinergic effects** can worsen cognitive function in Alzheimer's patients, making it unsuitable for their treatment.
*Memantine*
- **Memantine** is an **NMDA receptor antagonist** that helps regulate glutamate activity in the brain.
- It is used to treat **moderate to severe Alzheimer's disease** by preventing overstimulation of neurons.
*Rivastigmine*
- **Rivastigmine** is a **cholinesterase inhibitor** used to treat mild to moderate Alzheimer's disease.
- It works by increasing levels of **acetylcholine** in the brain, improving communication between nerve cells.
*Donepezil*
- **Donepezil** is another **cholinesterase inhibitor** commonly prescribed for mild to moderate Alzheimer's disease.
- It helps to improve **cognitive function** by enhancing cholinergic neurotransmission.
Stimulants and Cognitive Enhancers Indian Medical PG Question 9: Stimulant drugs are primarily given to children for the treatment of:
- A. Speech developmental disorder
- B. Conduct disorder
- C. ADHD (Correct Answer)
- D. Pervasive disorder
Stimulants and Cognitive Enhancers Explanation: ***ADHD***
- Stimulant medications like **methylphenidate** and **amphetamine** are first-line treatments for attention-deficit/hyperactivity disorder (ADHD) in children.
- They work by increasing the levels of **dopamine** and **norepinephrine** in the brain, improving focus and reducing impulsivity.
*Speech developmental disorder*
- This disorder primarily involves difficulties with **language production** or comprehension.
- Treatment typically focuses on **speech therapy** and educational interventions, not stimulant medications.
*Conduct disorder*
- This condition involves persistent patterns of **antisocial behavior**, aggression, and violations of rules.
- While therapy is the primary treatment, if there are co-occurring symptoms of ADHD, stimulants might be used to address those specific symptoms, but aren't a direct treatment for conduct disorder itself.
*Pervasive disorder*
- This term is an older term for what is now known as **autism spectrum disorder (ASD)**.
- There is no evidence that stimulant medications are effective for the core symptoms of ASD, and they might exacerbate some behavioral symptoms.
Stimulants and Cognitive Enhancers Indian Medical PG Question 10: The use of levodopa is avoided in which of the following patients?
- A. Amyotrophic lateral sclerosis
- B. Psychosis (Correct Answer)
- C. Alzheimer's disease
- D. Essential tremor
Stimulants and Cognitive Enhancers Explanation: ***Psychosis***
- Levodopa increases **dopaminergic activity** in the brain, which can significantly worsen or induce **psychotic symptoms** like hallucinations and delusions.
- Patients with pre-existing psychosis or a history of psychotic episodes are at high risk, making levodopa a **contraindicated** treatment.
*Alzheimer's disease*
- While Alzheimer's patients may experience motor symptoms, levodopa is generally not avoided unless there are specific **parkinsonian features** responsive to dopamine.
- The primary symptoms of Alzheimer's are **cognitive decline**, which levodopa does not treat and could potentially worsen agitation or confusion in advanced stages.
*Amyotrophic lateral sclerosis*
- **ALS** is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness and atrophy.
- Levodopa is **not effective** in treating ALS because the disease pathology does not involve dopamine deficiency.
*Essential tremor*
- Essential tremor is a movement disorder primarily treated with **beta-blockers** or **anti-seizure medications**.
- Levodopa has **no established efficacy** in treating essential tremor, and its use is unrelated to its pathophysiology.
More Stimulants and Cognitive Enhancers Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
oka